Target species
Horse.
Indications for use, for each target species
For intra-articular and intravenous treatment of lameness caused by joint dysfunction associated with non-infectious synovitis.
Contraindications
Do not use in cases of joint infection.
Special warnings
None.
Special precautions for use in animals
Special precautions for safe use in the target species:
Radiographic evaluation should be carried out in cases of acute, severe lameness to ensure that the joints are free from serious fractures.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Not applicable.
Special precautions for the protection of the environment:
Not applicable
Adverse events
Horse:
Common (1 to 10 animals/100 animals treated): | Injection site joint reaction (injection site swelling, injection site warmth) a |
a Transient and mild. Self-limiting swelling and/or heat in the treated joint resolve spontaneously within 48 hours, and do not negate a successful therapeutic outcome.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy, lactation or lay
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Pregnancy and lactation:
Use only according to the benefit/risk assessment by the responsible veterinarian.
Interaction with other medicinal products and other forms of interaction
No data available.
Administration route and dosage
Intraarticular and intravenous use.
Intravenous use: 3 ml intravenously repeated at weekly intervals for a total of three treatments.
For single intra-articular injection: 3 ml (51 mg) intra-articularly into medium sized and large joints. Smaller joints such as intertarsal, tarsometatarsal and interphalangeal joints can be treated with a 1.5 ml dose (25.5 mg).
More than one joint may be treated at the same time.
Excess synovial fluid should be removed whenever possible prior to injection.
Remove product from refrigerator approximately 10 minutes before performing injection. The injection should be administered under strict aseptic conditions. Ensure removal of dirt, hair, topical medicaments and soap/antiseptic residues. Intra-articular injections should not be made through overlying skin that is infected, blistered, scurfed or otherwise compromised. A sterile dressing and clean bandage should be applied after injection, as appropriate for the particular joint treated.
Symptoms of overdose (and where applicable, emergency procedures and antidotes)
Not reported.
Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Not applicable
Withdrawal period(s)
Meat and offal – zero days.